10,625 Shares in Krystal Biotech, Inc. $KRYS Purchased by Atika Capital Management LLC

Atika Capital Management LLC acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,625 shares of the company’s stock, valued at approximately $2,745,000.

A number of other institutional investors also recently added to or reduced their stakes in KRYS. Sei Investments Co. grew its stake in shares of Krystal Biotech by 44.1% in the 1st quarter. Sei Investments Co. now owns 46,570 shares of the company’s stock valued at $12,030,000 after purchasing an additional 14,260 shares during the period. Cetera Investment Advisers lifted its position in shares of Krystal Biotech by 34.4% during the 1st quarter. Cetera Investment Advisers now owns 6,206 shares of the company’s stock worth $1,603,000 after buying an additional 1,590 shares during the period. Measured Wealth Private Client Group LLC bought a new position in shares of Krystal Biotech during the 1st quarter worth approximately $472,000. First Trust Advisors LP boosted its stake in Krystal Biotech by 42.9% in the 1st quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock valued at $90,547,000 after buying an additional 105,245 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in Krystal Biotech by 17.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,985 shares of the company’s stock valued at $513,000 after buying an additional 289 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 26,642 shares of company stock valued at $8,243,923. 13.10% of the stock is currently owned by insiders.

Krystal Biotech Stock Down 2.8%

Shares of KRYS stock opened at $327.50 on Friday. The firm has a market cap of $9.65 billion, a price-to-earnings ratio of 43.78 and a beta of 0.50. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $382.54. The stock has a 50-day moving average price of $333.19 and a 200 day moving average price of $292.22.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. Sell-side analysts predict that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on KRYS shares. TD Cowen increased their price objective on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup upped their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Bank of America raised their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $360.67.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.